{Reference Type}: Case Reports
{Title}: Initial experience of enfortumab vedotin in a patient with metastatic urothelial carcinoma on hemodialysis: Two case reports.
{Author}: Mori S;Matsuo T;Honda H;Araki K;Mitsunari K;Ohba K;Mochizuki Y;Imamura R;
{Journal}: IJU Case Rep
{Volume}: 7
{Issue}: 4
{Year}: 2024 Jul
暂无{DOI}: 10.1002/iju5.12736
{Abstract}: <B>UNASSIGNED: </B>Few studies have reported on administering enfortumab vedotin to patients with metastatic urothelial carcinoma and end-stage renal disease requiring hemodialysis.<BR><B>UNASSIGNED: </B>Case 1: An 85-year-old man underwent hemodialysis for progressive renal failure 4 months after right laparoscopic radical nephroureterectomy. Case 2: A 73-year-old man underwent hemodialysis after two laparoscopic radical nephroureterectomies for recurrent urothelial carcinoma. In both cases, enfortumab vedotin was administered due to postoperative recurrence and progression despite platinum-based chemotherapy and pembrolizumab. Partial response and disease progression were observed in cases 1 and 2, respectively. Adverse events included a mild skin rash in both patients and neutropenia in Case 1, both of which resolved with symptomatic treatment.<BR><B>UNASSIGNED: </B>The efficacy and safety of enfortumab vedotin in patients with metastatic urothelial carcinoma, and end-stage renal disease undergoing hemodialysis, were confirmed.